-       Report 
   - August 2025
    -  187 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  184 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  196 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - September 2021
    -  40 Pages 
    China
   
   From       €2337EUR$2,600USD£2,049GBP 
                  -       Report 
   - November 2023
    -  353 Pages 
    Global
   
   From       €6831EUR$7,600USD£5,991GBP 
      €8539EUR$9,500USD£7,488GBP 
                   -       Drug Pipelines 
   - January 2023
    -  30 Pages 
    Global
   
   From       €1977EUR$2,200USD£1,734GBP 
      €2472EUR$2,750USD£2,168GBP 
                  -       Report 
   - May 2024
    -  130 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                      Exemestane is a type of drug used to treat lung cancer. It is a type of aromatase inhibitor, which works by blocking the production of estrogen in the body. This helps to reduce the growth of certain types of cancer cells that need estrogen to grow. Exemestane is used to treat postmenopausal women with hormone receptor-positive breast cancer. It is also used to reduce the risk of breast cancer in postmenopausal women who have a high risk of developing the disease.
Exemestane is available in tablet    form and is taken orally once a day. It is usually taken for five years or until the cancer has been treated. Common side effects of exemestane include hot flashes, joint pain, fatigue, nausea, and vomiting.
Exemestane is a widely used drug in the treatment of lung cancer. It is an important part of the treatment regimen for many patients, and is often used in combination with other drugs.
Some companies that produce exemestane include Pfizer, Novartis, and AstraZeneca. Show Less   Read more